| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Dahl Andrew M., SVP, Corporate Controller
Gave up 101 shares to cover exercise price or tax ($10.7K) |
| 10 Nov 2026 |
Form 4: Lippis Daniel J., CVP, TAVR
Received 619 shares by exercise or conversion ($45K) · Sold 619 shares ($64.5K) |
| 10 Nov 2026 | 144 |
| 09 Nov 2026 |
Form 4: Zovighian Bernard J, Director
Received 23,100 shares by exercise or conversion ($1.68M) · Sold 23,100 shares ($2.38M) |
| 09 Nov 2026 |
Form 4: Bobo Donald E Jr, CVP,Strategy/Corp Development
Received 48,900 shares by exercise or conversion ($3.55M) · Sold 48,900 shares ($5.04M) |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | 144 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, CA, November 4, 2026 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. |
| 08 Oct 2026 |
Form 4: Lippis Daniel J., CVP, TAVR
Received 619 shares by exercise or conversion ($45K) · Sold 619 shares ($53K) |
| 14 Sep 2026 |
Form 4: Markowitz Wayne, CVP, JAPAC
Gave up 355 shares to cover exercise price or tax ($30.8K) · Gave up 568 shares to cover exercise price or tax ($47.9K) |
| 14 Sep 2026 |
Form 4: Dahl Andrew M., SVP, Corporate Controller
Gave up 253 shares to cover exercise price or tax ($21.3K) |
| 11 Sep 2026 |
Form 4: Chopra Daveen, CVP, TMTT, Surgical & IHFM
Gave up 398 shares to cover exercise price or tax ($34.5K) |
| 11 Sep 2026 |
Form 4: Lippis Daniel J., CVP, TAVR
Received 619 shares by exercise or conversion ($45K) · Sold 619 shares ($54.2K) |
| 31 Aug 2026 |
Form 4: Dahl Andrew M., SVP, Corporate Controller
Sold 544 shares ($49.5K) |
| 31 Aug 2026 | 144 |
| 28 Aug 2026 |
Form 4: Bruls Annette, CVP, EMEACLA
Sold 2,644 shares ($238K) |
| 28 Aug 2026 | 144 |
| 28 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision ... |
| 26 Aug 2026 |
Form 4: Chopra Daveen, CVP, TMTT, Surgical & IHFM
Received 31,800 shares by exercise or conversion ($2.31M) · Sold 31,800 shares ($2.89M) |
Loading...